Product Program year 2025 Source: CMS Open Payments

Vanrafia

Drug Nephrology

NDC 0078-1420-15

Open in the dashboard

General payments

$380,412

5,486 payments

Research payments

$8,034,060

89 payments

Through program year 2025, $380,412 in general payments and $8,034,060 in research payments were reported against Vanrafia (Nephrology).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

2 rows
Year Kind Amount Payments
2025 General $380,412 5,486
2025 Research $8,034,060 89

Breakdown

Who paid General payments · program year 2025
  1. Novartis Pharmaceuticals Corporation $378,137 5,485 payments
  2. Novartis Pharma AG $2,275 1 payment
Top recipients General payments · program year 2025
  1. Graham Walker Emergency Medicine · Stanford, CA $70,500 19% · 3 payments
  2. Joseph Habboushe Emergency Medicine · New York, NY $70,500 19% · 3 payments
  3. Nissreen Elfadawy Nephrology · Chardon, OH $9,436 2% · 13 payments
  4. Arvind Madan Nephrology · Orlando, FL $9,245 2% · 11 payments
  5. Joel Topf Nephrology · Roseville, MI $8,091 2% · 3 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2025
  1. Nephrology Internal Medicine $183,300 49% · 1,811 practitioners
  2. Emergency Medicine $141,118 37% · 3 practitioners
  3. Nurse Practitioner, Family Nurse Practitioner $15,155 4% · 229 practitioners
  4. Nurse Practitioner $8,625 2% · 170 practitioners
  5. Internal Medicine $5,419 1% · 107 practitioners

The top 5 of 50 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2025
  1. New York $83,683 22% · 173 recipients
  2. California $83,357 22% · 90 recipients
  3. Florida $21,988 6% · 220 recipients
  4. Ohio $20,936 6% · 120 recipients
  5. Texas $19,757 5% · 285 recipients

The top 5 of 48 states; each share is of general payments naming this product in 2025 where a state was reported.

The top 25 states, free in the app

5,486 general · 89 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record